A detailed history of Verition Fund Management LLC transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Verition Fund Management LLC holds 69,628 shares of CCCC stock, worth $150,396. This represents 0.0% of its overall portfolio holdings.

Number of Shares
69,628
Holding current value
$150,396
% of portfolio
0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

BUY
$3.6 - $7.0 $250,660 - $487,396
69,628 New
69,628 $250,000
Q3 2023

Nov 14, 2023

SELL
$1.81 - $3.89 $78,937 - $169,650
-43,612 Reduced 58.15%
31,388 $58,000
Q2 2023

Aug 14, 2023

BUY
$2.75 - $3.77 $178,233 - $244,341
64,812 Added 636.16%
75,000 $206,000
Q1 2023

May 15, 2023

BUY
$3.1 - $9.02 $31,582 - $91,895
10,188 New
10,188 $31,000

Others Institutions Holding CCCC

About C4 Therapeutics, Inc.


  • Ticker CCCC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,913,800
  • Market Cap $106M
  • Description
  • C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...
More about CCCC
Track This Portfolio

Track Verition Fund Management LLC Portfolio

Follow Verition Fund Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Verition Fund Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Verition Fund Management LLC with notifications on news.